Advanced search
Start date

Lapatinib effects on Her2+ and Her2- canine mammary carcinoma cells cultured in vitro

Grant number: 18/14041-4
Support type:Scholarships in Brazil - Master
Effective date (Start): April 01, 2019
Effective date (End): August 31, 2020
Field of knowledge:Agronomical Sciences - Veterinary Medicine - Animal Clinics and Surgery
Principal researcher:Renee Laufer Amorim
Grantee:Antonio Fernando Leis Filho
Home Institution: Faculdade de Medicina Veterinária e Zootecnia (FMVZ). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil
Associated scholarship(s):19/26266-3 - Aryl hydrocarbon receptor regulation of canine ErbB4, BE.EP.MS


Breast neoplasms in female dogs, as well as in women, occur spontaneously and frequently. For this reason, the female dog is considered the main experimental model for this tumor in humans. Several drugs are used as adjuvant treatment for breast neoplasms, however some tumors do not respond adequately to established protocols. Lapatinib, a tyrosine kinase inhibitor, is a therapeutic alternative, especially against HER2+ neoplasms. HER2 is an upregulated proto-oncogene in 25 to 30% of breast neoplasms in women, and 21.8% in dogs. Thus, the study aims to evaluate the anti-tumor effect of lapatinib in canine mammary carcinoma HER2+ cells in vitro. The groups will be composed of HER2+ mammary carcinoma cells, HER2- mammary carcinoma cells and mammary cells without neoplastic alterations, treated or not with lapatinib. The samples will be obtained from a previously established canine mammary carcinoma cell bank. The concentration of lapatinib to inhibit 50% (IC 50) of cell growth will be determined. HER2 expression will be assessed by western blotting. Cell viability (tripan blue, MTT) and cell migration (wound healing) will be evaluated. Lapatinib is expected to inhibit HER2+ tumor growth as in humans, establishing its pathway in canine species. (AU)

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items